文献速递糖尿病骨质疏松与钙磷/甲状旁腺

AGE抑制剂吡哆胺对老年2型糖尿病女性骨骼的影响:一项随机临床试验

The Effects of the AGE Inhibitor Pyridoxamine on Bone in Older Women With Type 2 Diabetes: A Randomized Clinical Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

这项双盲随机对照试验纳入55例老年2型糖尿病女性,口服吡哆胺200 mg每日两次治疗1年。吡哆胺组P1NP升高23.0%(95%CI 9,37;组内P=.028),安慰剂组升高4.1%(-9,17;组内P=.576;组间P=.056);股骨颈骨密度吡哆胺组升高2.6±5% vs 安慰剂组下降0.9±4%(组间P=.007);HbA1c吡哆胺组下降0.38±0.7% vs 安慰剂组升高0.05±1.7%(组间P=.04)。作者认为吡哆胺有增加P1NP的趋势,并增加骨密度、降低HbA1c,需进一步研究。

要点

  • 吡哆胺组P1NP升高23.0%(95%CI 9,37;组内P=.028),安慰剂组升高4.1%(-9,17;组内P=.576;组间P=.056)。
  • 股骨颈骨密度吡哆胺组升高2.6±5% vs 安慰剂组下降0.9±4%(组间P=.007)。
  • HbA1c吡哆胺组下降0.38±0.7% vs 安慰剂组升高0.05±1.7%(组间P=.04)。

核心结论

  • 吡哆胺在老年2型糖尿病女性中有增加P1NP的趋势,并增加骨密度、降低HbA1c。
  • 作者认为需进一步研究吡哆胺作为针对疾病机制的方法以减少2型糖尿病骨折的潜力。

研究设计与样本

  • 学术中心开展的双盲随机对照试验,纳入老年2型糖尿病女性(n=55)。
  • 口服吡哆胺200 mg每日两次,治疗1年。
  • 主要结局为骨形成标志物P1NP的变化;其他结局包括骨吸收、骨密度、HbA1c和皮肤自发荧光的变化,以及在骨活检亚组中骨荧光AGEs与皮肤自发荧光的相关性。

主要发现

  • P1NP吡哆胺组升高23.0%(95%CI 9,37;组内P=.028)vs 安慰剂组升高4.1%(-9,17;组内P=.576;组间P=.056)。
  • 股骨颈骨密度吡哆胺组升高2.6±5% vs 安慰剂组下降0.9±4%(组间P=.007)。
  • 骨吸收标志物和皮肤自发荧光无变化。
  • HbA1c吡哆胺组下降0.38±0.7% vs 安慰剂组升高0.05±1.7%(组间P=.04)。
  • 吡哆胺组内HbA1c变化与P1NP变化百分比呈负相关(r=-0.50,P=.034);皮质骨活检骨荧光AGEs与皮肤自发荧光相关(r=0.86,P=.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者在结论中提出需进一步研究吡哆胺作为针对疾病机制的方法以减少2型糖尿病骨折的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Patients with type 2 diabetes (T2D) have reduced bone turnover and increased fractures. Advanced glycation end products (AGEs) impair osteoblasts and are implicated in diabetic fractures. Pyridoxamine (PM) is a vitamin B6 metabolite that inhibits formation of AGEs. OBJECTIVE: We hypothesized that PM treatment in older patients with T2D, by inhibiting AGEs, would increase bone formation. METHODS: This was a double-blind randomized controlled trial at an academic center. Older women with T2D were included (n = 55). Oral PM 200 mg twice daily for 1 year was given. The primary outcome was the change in the bone formation marker P1NP. Other outcomes were changes in bone resorption, bone mineral density (BMD), HbA1c, and skin autofluorescence (SAF), and in a bone biopsy subgroup, the correlation between bone fluorescent AGEs (fAGEs) and SAF. RESULTS: P1NP increased 23.0% with PM (95% CI 9, 37; within group P = .028) vs 4.1% with placebo (-9, 17; within group P = .576; between groups P = .056). BMD increased at the femoral neck (PM 2.6 ± 5% vs placebo -0.9 ± 4%; between groups P = .007). Bone resorption markers and SAF did not change. HbA1c decreased (PM -0.38 ± 0.7% vs placebo 0.05 ± 1.7%; between groups P = .04). Within the PM group, the HbA1c change correlated inversely with the % P1NP change (r = -0.50, P = .034). Cortical bone biopsy fAGEs correlated with SAF (r = 0.86, P = .001). Adverse events were similar between groups. CONCLUSION: PM tended to increase P1NP in older women with T2D, as well as increasing bone density and reducing HbA1c. Further studies are needed to investigate the potential of PM as a disease mechanism-directed approach to reduce fractures in T2D.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Brossfield AV, McMahon DJ, Fernando J, et al. The Effects of the AGE Inhibitor Pyridoxamine on Bone in Older Women With Type 2 Diabetes: A Randomized Clinical Trial. J Clin Endocrinol Metab. 2025. PMID: 39376018. doi:10.1210/clinem/dgae700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。